HRK inactivation is implicated in tumorigenesis across diverse cancer types (Hao et al. 2012), while HRK-expressing tumors demonstrate reduced proliferative capacity, diminished vascularization, and improved survival in murine models (Kaya-Aksoy et al. 2019). The gene discussed is HRK; the disease is cancer.